**Supplementary Table 1: Clinical characteristics by EF group and by country**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **New Zealand** | | | **Singapore** | | |
|  | **HFpEF**  **(LVEF >=50%)** | **HFmrEF**  **(LVEF 40-49%)** | **HFrEF**  **(LVEF < 40%)** | **HFpEF**  **(LVEF >=50%)** | **HFmrEF**  **(LVEF 40-49%)** | **HFrEF**  **(LVEF < 40%)** |
| N | 331 (35%) | 134 (14%) | 476 (51%) | 243 (22%) | 122 (11%) | 733 (67%) |
| Age | 73.9 (11.5) | 67.7 (12.9) | 65.9 (14.5) | 68.3 (11.4) | 63.6 (12.2) | 59.7 (11.6) |
| Women | 147 (44%) | 38 (28%) | 98 (21%) | 127 (52.2%) | 39 (32%) | 102 (14%) |
| Ethnicity |  |  |  |  |  |  |
| NZ European | 259 (78%) | 91 (68%) | 310 (65%) | 0 | 0 | 0 |
| Maori | 37 (11%) | 22 (16%) | 103 (22%) | 0 | 0 | 0 |
| Pacific | 20 (6%) | 16 (12%) | 47 (10%) | 0 | 0 | 0 |
| Chinese | 5 (2%) | 0 | 2 (0.4%) | 152 (63%) | 74 (61%) | 444 (61%) |
| Malay | 0 | 0 | 0 | 67 (27%) | 35 (29%) | 194 (26%) |
| Indian | 7 (2%) | 2 (2%) | 12 (3%) | 21 (9%) | 11 (9%) | 88 (12%) |
| Other | 3 (1%) | 3 (2%) | 2 (0.4%) | 3 (1%) | 2 (2%) | 7 (1%) |
| Medical History |  |  |  |  |  |  |
| Prior CAD | 157 (47%) | 69 (51%) | 231 (49%) | 79 (33%) | 65 (53%) | 431 (59%) |
| Prior MI | 92 (28%) | 49 (37%) | 159 (33%) | 28 (12% | 29 (24%) | 222 (30%) |
| Prior PCI | 53 (16%) | 27 (20%) | 66 (14%) | 28 (12%) | 26 (21%) | 160 (22%) |
| Prior CABG | 72 (22%) | 29 (22%) | 97 (20%) | 25 (10%) | 21 (17%) | 120 (16%) |
| Hypertension | 239 (72%) | 97 (72%) | 261 (55%) | 208 (86%) | 96 (79%) | 482 (66%) |
| Diabetes | 118 (36%) | 50 (37%) | 134 (28%) | 143 (59%) | 63 (52%) | 418 (57%) |
| Stroke | 52 (16%) | 19 (14%) | 67 (14%) | 26 (11%) | 13 (11%) | 81 (11%) |
| COPD | 101 (31%) | 40 (30%) | 109 (23%) | 17 (7%) | 14 (11%) | 62 (8.5%) |
| HF History |  |  |  |  |  |  |
| Ischaemic aetiology | 142 (43%) | 64 (48%) | 211 (44%) | 108 (44%) | 73 (60%) | 486 (66%) |
| Prior hosp adm for HF | 131 (40%) | 58 (43%) | 201 (42%) | 121 (50%) | 74 (61%) | 477 (65%) |
| HF device-therapies |  |  |  |  |  |  |
| ICD | 3 (1%) | 3 (2.2%) | 25 (5.3%) | 0 | 1 (2.3%) | 43 (6%) |
| CRT-D | 1 (0.3%) | 2 (1.5%) | 11 (2.3%) | 0 | 0 | 11 (1.5%) |
| CRT-P | 4 (1%) | 0 | 7 (1.5%) | 0 | 2 (1.6%) | 4 (0.6%) |
| AF\* | 218 (66%) | 85 (63%) | 259 (54%) | 78 (32%) | 41 (34%) | 142 (19%) |
| LBBB | 43 (13%) | 30 (22%) | 140 (29%) | 3 (1%) | 8 (6.6%) | 68 (9%) |
| Medications |  |  |  |  |  |  |
| ACE inhibitor/ARB | 79% | 87% | 89% | 77% | 89% | 84% |
| Beta-blocker | 77% | 81% | 86% | 81% | 85% | 89% |
| Loop diuretic | 90% | 96% | 95% | 80% | 84% | 92% |
| Spironolactone | 13% | 31% | 43% | 12% | 32% | 56% |
| Anticoagulant | 44% | 43% | 40% | 12% | 13% | 17% |
| Antiplatelet | 55% | 57% | 54% | 21% | 25% | 26% |
| Statin | 58% | 69% | 57% | 86% | 82% | 83% |
| Total medications, N | 7 (5,8) | 7 (6, 8) | 7 (5, 8) | 8 (6,9) | 8 (6,9) | 8 (7,9) |
| Clinical status |  |  |  |  |  |  |
| NYHA class, % | 16/50/29/5 | 14/50/27/7 | 20/42/30/7 | 23/60/12/1 | 25/65/9/1 | 25/64/75/2 |
| MLWHF score | 41.1 (23.0) | 46.6 (25.6) | 47.8 (25.0) | 30.4 (20.2) | 28.0 (22.3) | 33.6 (22.8) |
| Heart rate, bpm | 70 (13.4) | 72 (13) | 74 (14) | 72 (13.2) | 74 (13.0) | 78 (13.9) |
| SBP, mmHg | 128 (22.1) | 124 (22.0) | 116 (19.3) | 134 (21.6) | 136 (26) | 121 (20) |
| DBP, mmHg | 72 (12.0) | 74 (13.0) | 71 (12.0) | 70 (12.3) | 72 (14.5) | 71 (12.8) |
| Height, m | 1.68 (0.1) | 1.70 (0.09) | 1.72 (0.09) | 1.58 (0.08) | 1.61 (0.09) | 1.64 (0.08) |
| Weight, kg | 86.8 (23.4) | 94.1 (26.7) | 88.1 (24.8) | 69.5 (15.3) | 69.7 (16.3) | 69.4 (15.9) |
| Laboratory variables |  |  |  |  |  |  |
| Creatinine, micromol/L | 109 (87, 143) | 101 (88, 129) | 106 (89, 134) | 104 (79, 138) | 102 (79, 139) | 104.5 (86, 131) |
| Sodium, mmol/L | 140 (138, 142) | 140 (138, 142) | 139 (137, 141) | 139 (137, 141) | 139 (136, 141) | 138 (136, 140) |
| Haemoglobin, g/dL | 128 (114, 142) | 135 (124, 146) | 138 (125, 149) | 118 (101, 133) | 127 (112, 140) | 134 (119, 147) |
| NT-proBNP, pg/mL | 1350 (571, 2462) | 1545 (697, 2569) | 2057 (1012, 4242) | 1004 (345, 2385) | 1532 (578, 3035) | 2527 (1249, 5825) |
| Echo data |  |  |  |  |  |  |
| LVEDVi, ml/m2 | 50 (39, 67) | 75 (58, 91) | 96 (76, 117) | 47 (37, 57) | 65 (53, 74) | 89 (72, 113) |
| LVESVi, ml/m2 | 20 (14, 27) | 42 (32, 52) | 68 (53, 86) | 19 (14, 25) | 36 (30, 43) | 66 (51, 87) |
| LVEF, % | 61 (57, 65) | 44 (42, 46) | 28 (23, 34) | 59 (55, 63) | 44 (41, 47) | 25 (20, 30) |
| LAvoli, ml/m2 | 49 (37, 64) | 49 (39, 60) | 55 (42, 68) | 34 (26, 52) | 36 (28, 53) | 41 (31, 54) |
| E/e’ average | 13 (10, 16) | 12 (9, 17) | 14 (11, 19) | 13 (10, 17) | 15 (12, 19) | 17 (13, 22) |
| Number of deaths | 56 (17%) | 18 (13%) | 108 (23%) | 24 (9.9%) | 12 (9.8%) | 125 (17%) |